Viking Therapeutics (VKTX) Equity Average: 2015-2025
Historic Equity Average for Viking Therapeutics (VKTX) over the last 11 years, with Sep 2025 value amounting to $754.2 million.
- Viking Therapeutics' Equity Average fell 17.68% to $754.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $754.2 million, marking a year-over-year decrease of 17.68%. This contributed to the annual value of $614.3 million for FY2024, which is 148.85% up from last year.
- Viking Therapeutics' Equity Average amounted to $754.2 million in Q3 2025, which was down 8.15% from $821.2 million recorded in Q2 2025.
- In the past 5 years, Viking Therapeutics' Equity Average registered a high of $927.4 million during Q2 2024, and its lowest value of $139.7 million during Q1 2023.
- In the last 3 years, Viking Therapeutics' Equity Average had a median value of $754.2 million in 2025 and averaged $632.3 million.
- Its Equity Average has fluctuated over the past 5 years, first declined by 28.53% in 2022, then skyrocketed by 358.97% in 2024.
- Quarterly analysis of 5 years shows Viking Therapeutics' Equity Average stood at $207.5 million in 2021, then decreased by 28.53% to $148.3 million in 2022, then spiked by 141.62% to $358.3 million in 2023, then soared by 150.01% to $895.9 million in 2024, then dropped by 17.68% to $754.2 million in 2025.
- Its last three reported values are $754.2 million in Q3 2025, $821.2 million for Q2 2025, and $863.6 million during Q1 2025.